A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
DNA wrapped around histone octamers in nucleosomes occludes transcription factor binding sites and represses genes. ATP-dependent chromatin-remodeling complexes (SWI/SNF, ISWI, CHD, INO80 families) use energy from ATP hydrolysis to slide, eject, or restructure nucleosomes, exposing DNA and enabling transcription factor access. This remodeling is dynamic and reversible, allowing cells to rapidly alter gene expression. Mutations in chromatin-remodeling genes are found in ~20% of human cancers, highlighting their importance in gene regulation.
From your study of nuclear organization, you know that eukaryotic DNA is not floating freely — it is packaged into chromatin, a complex of DNA wound around histone proteins. The fundamental unit is the nucleosome: 147 base pairs of DNA wrapped roughly 1.7 times around an octamer of histone proteins (two each of H2A, H2B, H3, and H4). This packaging solves a space problem — fitting two meters of DNA into a nucleus just micrometers across — but it creates an access problem. A transcription factor that needs to bind a specific DNA sequence may find that sequence buried against the histone surface, physically blocked from interaction.
Chromatin remodeling is the cell's solution. Dedicated protein complexes use the energy of ATP hydrolysis to physically alter the position or composition of nucleosomes. The SWI/SNF family (named for yeast mutants defective in mating-type switching and sucrose non-fermenting) can slide nucleosomes along DNA, exposing previously occluded sequences, or eject nucleosomes entirely, creating nucleosome-free regions at gene promoters. The ISWI family tends to do the opposite — spacing nucleosomes evenly and promoting a more compact, repressive chromatin state. CHD (chromodomain helicase DNA-binding) complexes read histone modifications and reposition nucleosomes accordingly. INO80 complexes can exchange histone variants — swapping standard H2A for the variant H2A.Z, which loosens DNA-histone contacts and facilitates transcription.
The key insight is that chromatin remodeling is not an all-or-nothing switch — it is a tunable, reversible regulatory mechanism. A gene can be made more or less accessible depending on which remodeling complexes are recruited, and recruitment depends on transcription factors, histone modifications, and signaling pathways. This creates a layered control system: the DNA sequence determines what a gene can encode, but chromatin accessibility determines whether that gene is actually read. Two cells with identical DNA — say, a neuron and a liver cell — express entirely different gene sets largely because their chromatin landscapes differ, with different regions opened or closed by remodeling activity.
The importance of this system is underscored by what happens when it breaks. Mutations in SWI/SNF subunits (such as SMARCB1 and ARID1A) are among the most frequent alterations in human cancers, found in approximately 20% of all tumors. When a remodeling complex cannot open chromatin at tumor suppressor gene promoters, those genes are silenced even though the DNA sequence is intact — the cell loses a brake on proliferation not because the brake pedal is broken, but because a barrier is blocking access to it. This realization has spurred development of drugs targeting chromatin remodeling and its downstream effects, recognizing that gene regulation failures caused by packaging defects can be just as consequential as mutations in the genes themselves.